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A B S T R A C T   
The accumulation of β-amyloid (Aβ) aggregates in the brain occurs early in the progression of Alzheimer’s 
disease (AD), and non-fibrillar soluble Aβ oligomers are particularly neurotoxic. During binding to Aβ fibrils, 
curcumin, which can exist in an equilibrium state between its keto and enol tautomers, exists predominantly in 
the enol form, and binding activity of the keto form to Aβ fibrils is much weaker. Here we described the strong 
binding activity the keto form of curcumin derivative Shiga-Y51 shows for Aβ oligomers and its scant affinity for 
Aβ fibrils. Furthermore, with imaging mass spectrometry we revealed the blood-brain barrier permeability of 
Shiga-Y51 and its accumulation in the cerebral cortex and the hippocampus, where Aβ oligomers were mainly 
localized, in a mouse model of AD. The keto form of curcumin derivatives like Shiga-Y51 could be promising seed 
compounds to develop imaging probes and therapeutic agents targeting Aβ oligomers in the brain.   
1. Introduction 
Alzheimer’s disease (AD) is characterized by progressive cognitive 
impairment as a consequence of neuronal and synaptic loss and neuro-
transmitter deficits. The pathological features of AD are extracellular 
senile plaques and intracellular neurofibrillary tangles, comprising 
fibrillar β-amyloid (Aβ) aggregates and hyperphosphorylated tau, 
respectively [1,2]. The molecular genetics of familial AD supports the 
amyloid hypothesis; the accumulation of Aβ aggregates in the brain 
occurs early in the progression of AD [2,3], and Aβ oligomers are 
particularly neurotoxic [4]. The development of compounds that target 
Aβ oligomers is thus crucial in the diagnosis and therapeutic treatment 
of AD. 
Curcumin, a low molecular weight yellow-orange pigment in Cur-
cuma longa, reportedly binds to Aβ fibrils and Aβ oligomers in vitro and 
in vivo [5–8]. Curcumin can exist in an equilibrium state between its 
keto and enol tautomers. Previously, we found that the curcumin de-
rivatives bound to Aβ fibrils predominantly in the enol form [9], and also 
demonstrated that the binding activity of the keto form of curcumin 
derivatives to Aβ fibrils was much weaker [9]. These findings suggested 
the possibility that the keto form of curcumin derivatives binds to Aβ 
oligomers. 
Here, we synthesized a novel curcumin derivative—Shiga- 
Y51—with fixed keto forms (Fig. 1), and investigated its binding activity 
to Aβ oligomers in vitro and in vivo to address this knowledge gap. The 
results indicated that the keto form of curcumin derivatives holds great 
potential as an imaging probe and therapeutic agent targeting Aβ olig-
omers . 
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2. Materials and methods 
2.1. General methods 
We recorded all 1H NMR and 19F NMR spectra on an ECZ-400S 400 
MHz NMR spectrometer (JEOL, Tokyo, Japan). We report 1H chemical 
shifts in ppm (δ) relative to the internal standard, tetramethylsilane 
(TMS), and chemical shifts in the 19F spectra in ppm (δ) relative to the 
external standard, C6F6, at − 163 ppm. 
2.2. Preparation of Shiga-Y51 
2.2.1. Preparation of 4-methoxymethoxy-3-(trifluoromethoxy)benzalde-
hyde (II in Fig, 2) 
We slowly added chloromethyl methyl ether (1.07 mL, 0.014 mol) to 
a chilled mixture of 4-hydroxy-3-(trifluoromethoxy)benzaldehyde (2.06 
g, 0.01 mol) and potassium carbonate (2.21 g, 0.016 mol) in acetone (18 
mL). We stirred the mixture at room temperature for 10 h. We then 
evaporated the solvent in vacuo, and extracted the residue with ethyl 
acetate. We washed the extract with water, saturated sodium hydrogen 
carbonate, and an aqueous sodium chloride solution. After drying the 
extract over magnesium sulfate, we evaporated the solvent under 
reduced pressure. We separated the residue chromatographically on 
silica gel, and collected the fraction eluting in a 1:3 mixture of ethyl 
acetate and hexane to yield 4-methoxymethoxy-3-(trifluoromethoxy) 
benzaldehyde (2.48 g, 99%) as a colorless oil. 
2.2.2. Preparation of 1,7-bis(4′-methoxymethoxy-3′-trifluoromethoxy) 
phenyl-4-ethyl-1,6-heptadiene-3,5-dione (III in Fig, 2) 
We heated a mixture of 3-ethyl-2,4-pentanedione (256 mg, 2.0 
mmol) and boron trioxide (140 mg, 2.0 mmol) in ethyl acetate (4 mL) at 
70 ◦C for 0.5 h. We added tributyl borate (1.08 mL, 4.0 mmol) and a 
solution of 4-methoxymethoxy-3-trifluoromethoxy)benzaldehyde (1.00 
g, 4.0 mmol) to the mixture, and heated it at the same temperature for 
0.5 h. We added butylamine (0.20 mL, 2.0 mmol) to the mixture, and 
then heated it at 70 ◦C for 5 h. We added hydrochloric acid (2 M, 10 mL) 
to the mixture after it cooled, and vigorously stirred it for 0.5 h at room 
temperature. We extracted the mixture with ethyl acetate, and washed 
the extract with water and aqueous sodium chloride. After drying the 
extract over magnesium sulfate, we removed the solvent under reduced 
pressure. We purified the residue via silica gel chromatography, and 
collected the fraction eluting in a 1:3 mixture of ethyl acetate and 
hexane. We allowed the fraction to stand at room temperature and so-
lidify. We collected 1,7-Bis(4′-methoxymethoxy-3′-trifluoromethoxy) 
phenyl-4-ethyl-1,6-heptadiene-3,5-dione (282 mg, 23.9%) following 
trituration with hexane. Melting point: 124◦C-125 ◦C; 19F NMR (CDCl3): 
δ-59.50 (s); 1H NMR (CDCl3): δ1.20 (3H, t, J = 7.2 Hz), δ2.58 (2H, q, J =
7.2 Hz), δ3.50 (6H, s), δ5.26 (4H, s), δ6.96 (2H, d, J = 15.6 Hz), δ7.2–7.3 
(2H), δ7.4–7.5 (4H), δ7.67 (2H, d, J = 15.6 Hz), δ17.38 (1H, s). 
2.2.3. Preparation of 1,7-bis(4′-methoxymethoxy-3′-trifluoromethoxy) 
phenyl-4-ethyl-4-methyl-1,6-heptadiene-3,5-dione (IV in Fig, 2) 
We added potassium carbonate (550 mg, 4.0 mmol) to a solution of 
1,7-bis(4′-methoxymethoxy-3′-trifluoromethoxy)phenyl-4-ethyl-1,6- 
heptadiene-3,5-dione (237 mg, 0.40 mmol) and methyl iodide (0.25 mL, 
4.0 mmol) in acetone (10 mL), and heated the mixture at 50◦C-55 ◦C for 
3 h. We evaporated the solvent in vacuo, and extracted the residue with 
ethyl acetate. After washing the extract with water and a saturated sa-
line solution, we dried it over magnesium sulfate. We evaporated the 
solvent under reduced pressure and separated the residue chromato-
graphically on silica gel. From the fraction eluting in a 1:3 mixture of 
ethyl acetate and hexane we acquired 1,7-bis(4′-methoxymethoxy-3′- 
trifluoromethoxy)phenyl-4-ethyl-4-methyl-1,6-heptadiene-3,5-dione 
(230 mg, 95.0%) as a pale yellow oil. 19F NMR (CDCl3): δ-59.59 (s); 1H 
NMR (CDCl3): δ0.82 (3H, t, J = 7.2 Hz), δ1.42 (3H, s), δ2.05 (2H, q, J =
7.2 Hz), δ3.46 (6H, s), δ5.23 (4H, s), δ6.65 (2H, d, J = 15.6 Hz), δ7.17 
(2H, d, J = 8.4 Hz), δ7.38 (2H, br, s), δ7.40 (2H, dd, J = 2 Hz, 8.4 Hz), 
δ7.62 (2H, d, J = 15.6 Hz). 
2.2.4. Preparation of 1,7-bis(4′-hydroxy-3′-trifluoromethoxy)phenyl-4- 
ethyl-4-methyl-1,6-heptadiene-3,5-dione (Shiga-Y51) 
We added 1 M HCl (1.80 mL, 1.80 mmol) to a solution of 1,7-bis(4′- 
Fig. 1. Chemical structures of Shiga-Y5, Shiga-Y17, and Shiga-Y51.  
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methoxymethoxy-3′-trifluoromethoxy)phenyl-4-ethyl-4-methyl-1,6- 
heptadiene-3,5-dione (182 mg, 0.30 mmol) in ethanol (6.0 mL), and 
heated the mixture at 60◦C-65 ◦C for 4 h. We evaporated the solvent 
under reduced pressure, and extracted the residue with ethyl acetate. 
After washing the extract with water and a saturated saline solution, we 
dried it over magnesium sulfate. We removed the solvent in vacuo, and 
separated the residue on a silica gel chromatography column. We 
collected the fraction eluting in a 1:3 mixture of ethyl acetate and 
hexane and dissolved it in a small amount of ethyl acetate. We added 
hexane to the solution to afford 1,7-bis(4′-hydroxy-3′-trifluoromethoxy) 
phenyl-4-ethyl-4-methyl-1,6-heptadiene-3,5-dione (101 mg, 65%) as 
colorless crystals. Melting point: 89◦C-91 ◦C; 19F NMR (CDCl3): δ-59.22 
(s); 1H NMR (CDCl3): δ0.82 (3H, t, J = 7.2 Hz), δ1.42 (3H, s), δ2.05 (2H, 
q, J = 7.2 Hz), δ5.69 (2H, s), δ6.64 (2H, d, J = 15.6 Hz), δ7.01 (2H, d, J 
= 8.4 Hz), δ7.35 (2H, br, s), δ7.39 (2H, dd, J = 2 Hz, 8.4 Hz), δ7.61 (2H, 
d, J = 15.6 Hz). Because a silica gel thin layer chromatography plate 
eluted with 1:3 ethyl acetate:hexane showed only one spot, we deemed 
the material sufficiently pure for use. However, we purified it further by 
recrystallizing it from a 1:3 mixture of ethyl acetate and n-hexane to 
determine its melting point (90.5◦C-91.5 ◦C). 
2.3. Preparation of Aβ aggregates 
We prepared Aβ oligomers and fibrils using previously reported 
protocols [10]. Briefly, we prepared a 1 mM mixture of Aβ1–42 peptides 
(Peptide Institute, Osaka, Japan) in 1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP; Wako, Osaka, Japan) and incubated it at 37 ◦C for 1 h. HFIP 
broke hydrogen bonds and eliminated pre-existing structural in-
homogeneities in the Aβ peptides [11]. We removed the HFIP by evap-
oration under reduced pressure, and stored the HFIP-treated Aβ peptides 
at − 30 ◦C. Prior to use, we dissolved the treated Aβ peptides in dimethyl 
sulfoxide (DMSO) to a concentration of 5 mM. To prepare the Aβ fibrils, 
we diluted the Aβ solution to 100 μM in 10 mM phosphate-buffered 
saline (PBS) and incubated it for 48 h at 37 ◦C. We prepared the Aβ 
oligomers (globulomers) according to the method reported by Barghorn 
et al. [12]. We diluted the Aβ peptides dissolved in DMSO at a concen-
tration of 400 μM in PBS with 0.2% sodium dodecyl sulfate (SDS) and 
incubated them for 6 h at 37 ◦C. We then diluted the mixture to 100 μM 
with H2O and incubated it for 18 h at 37 ◦C. Following centrifugation at 
14,000×g for 10 min at 4 ◦C, we collected the oligomer-enriched su-
pernatant and utilized it for Western blotting and quartz crystal micro-
balance (QCM) analysis. We confirmed the formation of globulomers by 
Western blotting, detecting bands in the range from 35 to 50 kDa 
(Supplementary Fig. 1), and QCM analysis showing significant binding 
of Shiga-Y5—but no significant binding of ThT—to 
globulomer-immobilized electrodes. 
To prepare intermediate Aβ aggregates with different aggregation 
periods, we incubated Aβ peptides at 50 μM in PBS at 26 ◦C with a dry 
block incubator for 0, 4, 8, and 12 h, and stored at − 30 ◦C before use. 
2.4. Western blot analysis 
We performed Western blot analysis to confirm aggregation of the Aβ 
peptides. We then subjected the Aβ aggregates to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) without a 
reducing agent, and subsequent Western blotting to determine their 
molecular weight and purity. We diluted the Aβ aggregates to 25 μM and 
mixed with an equal volume of non-reducing Laemmli buffer (Bio-Rad 
Laboratories, Hercules, CA, USA) without heating. We separated them 
via SDS-PAGE in a precast 15% polyacrylamide gel (SuperSep Ace, 
Wako) at 20 mA for 60 min, thereafter transferring them to Immobilon-P 
polyvinylidene difluoride (PVDF) membranes (Millipore, Burlington, 
MA, USA). We blocked the membranes using 5% skim milk in 25 mM 
Tris-buffered saline (pH 7.4) containing 0.1% Tween-20 (TBS-T) for 60 
min. We incubated the blots for 60 min with rabbit polyclonal anti- 
human Aβ (N-terminal) antibody (1:500; Product code 18584; 
Immuno-Biological Laboratories, Fujioka, Japan) or mouse monoclonal 
anti-Aβ E22P antibody [13–15] (clone 11A1; 1:100; Immuno-Biological 
Laboratories) in TBS-T at room temperature, and then washed them in 
TBS-T. We incubated the membranes with goat anti-rabbit IgG (H + L) 
antibody (1:10,000; Thermo Scientific, Rockford, IL, USA) conjugated to 
horseradish peroxidase, followed by SuperSignal West Pico chemilu-
minescent substrate (ThermoFisher Scientific, Waltham, MA, USA). We 
detected the signal using an ImageQuant LAS 4000 system (GE 
Healthcare, Buckinghamshire, UK). 
2.5. Quartz crystal microbalance (QCM) analysis 
We determined the binding affinities of Shiga-Y5, Shiga-Y17 and 
Shiga-Y51 for the Aβ aggregates using an AffinitxQ 27 MHz QCM 
analyzer (Initium, Tokyo, Japan). The QCM was equipped with a quartz 
plate 8 mm in diameter and a 4.9 mm2 Au electrode. We calibrated the 
quantity of adsorbed compound on the Au electrode surface 20 min after 
injection to change the frequency by 1 Hz in response to a 0.62 ng in-
crease in mass over a 1 cm2 area on the electrode. This corresponded to a 
1 Hz decrease in frequency for each 30 pg increase in the mass of the 4.9 
mm2 electrode [16]. To immobilize the Aβ fibrils on the electrode, we 
Fig. 2. Preparation of Shiga-Y51. We reacted 4-Hydroxy-3-(trifluoromethoxy) 
benzaldehyde (I) with chloromethyl methyl ether under basic conditions to 
protect the phenolic group on the benzaldehyde. We condensed the protected 
benzaldehyde derivative (II) with 3-ethyl-2,4-pentanedione to obtain the 4- 
ethyl curcumin derivative (III) using classical methods employed for curcu-
min synthesis. However, harsher reaction conditions were required to prepare 
curcumin derivative III than those used for the derivatives without phenolic 
protecting groups. We introduced the methyl group to compound III by heating 
it with methyl iodide in acetone under basic conditions. Finally, we removed 
the methoxymethoxyl group via the acid hydrolysis of derivative IV to obtain 
1,7-bis(4′-hydroxy-3′-trifluoromethoxy)phenyl-4-ethyl-4-methyl-1,6-hepta-
diene-3,5-dione (Shiga-Y51). 
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placed 2 μL of Aβ fibrils (200 pmol) on the electrode and allowed it to 
dry for 60 min at RT. To immobilize the Aβ oligomers, we placed 2 μL of 
the Aβ mixture on the electrode, and stored it overnight at 4 ◦C in a 
humid refrigerator, then dried it for 24 h at 4 ◦C. Prior to QCM analysis, 
we washed the electrode with water and placed it in the QCM vessel, 
which contained 8 mL of PBS maintained at 25 ◦C with stirring at 1000 
rpm. After the electrode had stabilized, we added 8 μL of Shiga-Y5, 
Shiga-17, Shiga-51 and thioflavin T (ThT; Anaspec, Fremont, CA, 
USA) in DMSO to the reaction vessel. The final concentrations of 
Shiga-Y5, Shiga-Y17, and Shiga-Y51 were 10 μM each, and the final 
concentration of ThT was 30 μM. We then recorded the changes in fre-
quency for 20 min. 
2.6. Animals 
We obtained APPswe/PS1dE9 double transgenic (APP/PS1) mice 
with a C57BL/6 background from Jackson Laboratory (Bar Harbor, ME, 
USA). The APP/PS1 mice expressed a chimeric mouse/human amyloid 
precursor protein (APP) with the K594 N and M595L mutations linked to 
Swedish familial AD (Mo/HuAPP695swe) and human PS1, carrying the 
exon 9 deletion associated with familial AD (PS1dE9) [17]. We bred 
heterozygous males with noncarrier females. We collected ear punches 
from the offspring, and genotyped the mice using a PCR. We used mice 
that did not express the transgene as wild-type controls. We housed the 
mice in standard laboratory cages at 23 ◦C with free access to water and 
food, and maintained a 12-h light/dark cycle with the lights on from 
8:00 to 20:00. All animal experiments complied with the ARRIVE 
guidelines, were carried out in accordance with the National Institutes of 
Health guide for the care and use of Laboratory animals (NIH Publica-
tions No. 8023, revised 1978), and were approved by the Animal Care 
and Use Committee at the Shiga University of Medical Science (Number. 
2018-2-12). 
2.7. Imaging mass spectrometry 
We injected Shiga-Y51 in 10% Cremophor EL (Nacalai Tesque, 
Kyoto, Japan) into the tail veins of APP/PS1 mice and wild-type mice 
aged 15–18 months at a dose of 200 mg/kg. We introduced Shiga-Y51 
through either bolus injection or continuous injection at a rate of 0.5 
mg/kg/mL over 20 min, and deeply anesthetized the mice with sodium 
pentobarbital at a dose of 50 mg/kg (I.P.). We sacrificed the mice 30 min 
after the completion of the injection with an overdose of sodium 
pentobarbital (200 mg/kg), which we injected intraperitoneally. We 
quickly removed the brains, cut along the sagittal plane, and immersed 
them in cold 2% carboxymethylcellulose on dry ice. Using a cryostat, we 
prepared 10 μm brain sections, which we mounted on glass slides coated 
with indium tin oxide (Matsunami Glass, Kishiwada, Japan). 
We vapor-deposited the samples using 9AA as a negative mode ma-
trix under dry vacuum conditions, performing the sublimation of 9AA at 
220 ◦C for 9 min using SVC-700TMSG/7PS80 vacuum vapor deposition 
equipment (Sanyu Electron, Tokyo, Japan). We performed imaging mass 
spectrometry using an iMScope matrix-assisted laser desorption/ioni-
zation MS (Shimadzu, Kyoto, Japan) in negative reflection mode. To 
acquire the mass spectra, we scanned the samples using a 1000 Hz Nd: 
YAG laser with 50 accumulating shots. The detector voltage and sample 
voltage were 1.66 kV and 3 kV, respectively. We collected spectra over 
the m/z range from 150 to 600 at a scan pitch of 25 μm, and an intensity 
of the iMScope laser ranging from 40 to 53. We performed MS/MS 
analysis to evaluate the target molecules, and verified the spectral data 
using an iMScope standard sample. We analyzed the data using the 
Imaging MS Solution™ software package (Shimadzu, Kyoto, Japan). 
2.8. Blood-brain barrier permeability of Shiga-Y51 
We intravenously injected male wild-type mice at 6.5 months with 
Shiga-Y51 in 10% Cremophor EL (Nacalai Tesque, Kyoto, Japan) at a 
dose of 200 mg/kg via bolus injection. We sacrificed the mice 30 min 
after injection via intraperitoneal injection of an overdose of sodium 
pentobarbital (200 mg/kg). We quickly removed the brains and stored 
them at − 80 ◦C until use. We homogenized the brains in methanol, and 
centrifuged the homogenates at 18,000×g for 10 min at 4 ◦C. We 
analyzed the supernatants via LC-MS/MS (QTRAP5500; Sciex, MA, 
USA) to quantify Shiga-Y51. 
2.9. Immunohistochemistry 
We fixed the mouse brains of the rest of the IMS study with 4% 
paraformaldehyde in PB, embedded in paraffin, and sectioned into 5 μm 
thickness. We deparaffinized the sections and treated them with 0.3% 
hydrogen peroxide in PBS at RT for 20 min to eliminate endogenous 
peroxidase activity, thereafter incubating the sections with 70% formic 
acid solution for 12 min. After several washes with PBS, we heated the 
sections in 1 mM EDTA (pH8.0) with a microwave oven. After rinsing in 
PBS, we blocked the sections with 3% BSA in PBS that contained 0.3% 
Triton X-100 (PBS-T) for 30 min to block non-specific protein binding. 
We then incubated the sections with rabbit polyclonal anti-human Aβ 
(N-terminal) antibody (1:200; Product code 18584; Immuno-Biological 
Laboratories) or mouse monoclonal anti-Aβ E22P antibody (clone 
11A1; 1:50; Immuno-Biological Laboratories) in PBS-T containing 0.2% 
BSA overnight at 4 ◦C, followed by incubation with biotinylated anti- 
rabbit IgG (1:1000; Vector Laboratories, Burlingame, CA, USA) or bio-
tinylated anti-mouse IgG (1:2000; Vector Laboratories) for 1 h at room 
temperature. We then incubated the sections with the avidin-biotin- 
peroxidase complex (Vectastatin ABC Elite kit, 1:1000; Vector Labora-
tories) for 1 h. We washed all sections several times with PBS-T between 
each step, and then revealed labeling by 3,3′-diaminobenzidine (DAB; 
Dojindo Laboratories, Kumamoto, Japan). We then coverslipped the 
sections with Entellan (Merck Millipore). 
2.10. Fluorescence competition assay 
We diluted Aβ fibrils and oligomers prepared as above to 5 μM in 
PBS, and transferred 100 μL of the Aβ to wells of a black 96-well non- 
binding plate (Greiner Bio-One, Kremsmünster, Austria). Thereafter, 
we added test compounds (10 μL of 0.2, 0.6, 2, 6, 20, 60, 200, and 600 
μM each in DMSO) to the wells. We diluted curcumin dissolved at 5 mM 
in DMSO to 5 μM in PBS, and added 90 μL of the solution to each well. 
After mixing and placing the wells for 30 min at room temperature 
under dark conditions, we measured the fluorescence with a microplate 
reader (Infinite M200, Tecan, Zürich, Switzerland) at an excitation 
wavelength of 430 nm and an emission wavelength of 510 nm for cur-
cumin. We estimated the binding activities to Aβ of the test com-
pounds—expressed as the half-maximal inhibitory concentrations (IC50) 
with regard to fluorescence—using GraphPad Prism 7 (GraphPad Soft-
ware, La Jolla, CA, USA). 
2.11. Thioflavin T fluorescence assay 
We mixed 20 μM Aβ 1–42 peptides in PBS with or without 10 μM 
Shiga-Y51, and subsequently incubated them in the presence of 5 μM 
ThT at a total volume of 100 μL in a 96-well black microplate at room 
temperature. We then measured fluorescence intensity with an excita-
tion of 440 nm and an emission of 485 nm using a microplate reader 
(Infinite M200; Tecan) with 10 s of agitation every 10 min for 480 min. 
2.12. Statistical analysis 
We performed statistical analyses using the GraphPad Prism 7 soft-
ware package (GraphPad Software, La Jolla, CA, USA). We report data as 
the mean ± the standard error of the mean (SEM). We determined sta-
tistical significance with Mann–Whitney tests for single comparisons, 
and with one-way analysis of variance (ANOVA) followed by Dunnett 
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tests for multiple comparisons. We considered p-values of <0.05 statis-
tically significant. 
3. Results 
3.1. Novel curcumin derivatives with fixed keto form 
We synthesized the novel curcumin derivative Shiga-Y51, which had 
methyl and ethyl groups at the C4 position, as a model of a keto form of 
curcumin derivative (Fig. 1). Here, in addition to Shiga-Y51, we used 
Shiga-Y5 [9] as a model of a curcumin derivative with keto–enol 
tautomerism and Shiga-Y17 [9] as another model of a keto form of 
curcumin derivative. 
3.2. Binding activity of curcumin derivatives to Аβ oligomers and fibrils 
We prepared the Аβ oligomers and fibrils as reported previously [8] 
(Supplementary Fig. 1a), and then investigated the interaction of 
Shiga-Y5, Shiga-Y17 and Shiga-Y51 with Аβ oligomers and fibrils using 
QCM analysis (Fig. 3; Supplementary Fig. 2). When we added Shiga-Y5 
to the QCM vessel at a final concentration of 10 μM, the frequencies of 
the electrodes on which Aβ fibrils and globulomers were immobilized 
decreased significantly (Supplementary Fig. 2a and e). In Fig. 3a, e, we 
compare the quantities of Shiga-Y5 bound to immobilized Aβ fibrils and 
globulomers on the QCM electrode to those of the control. The addition 
of Shiga-Y17 (Fig. 3f; Supplementary Fig. 2f) and of Shiga-Y51 (Fig. 3g; 
Supplementary Fig. 2g) significantly decreased the frequency of the 
globulomer-immobilized electrode. The addition of Shiga-Y17 signifi-
cantly reduced the frequency of the fibril-immobilized electrode 
(Fig. 3b; Supplementary Fig. 2b) and a reduction not induced by 
Shiga-Y51 (Fig. 3c; Supplementary Fig. 2c). We observed a significant 
decrease in the frequency of the electrode with immobilized Aβ fibrils 
after adding thioflavin T (ThT; 30 μM) to the QCM vessel, which is used 
as an indicator of Aβ fibrils, but in the presence of ThT there was no 
difference between the control and the electrode with respect to 
immobilized globulomers (Fig. 3d, h; Supplementary Fig. 2d and h). We 
calculated quantities of the compounds bound to Aβ oligomers and fi-
brils over a period of 20 min (Table 1). Shiga-Y51, Shiga-Y17, Shiga-Y5, 
and ThT were bound to Aβ oligomers and fibrils in molecular ratios of 
2.57, 2.52, 1.29, and 0.24, respectively (Table 1). These results indi-
cated that Shiga-Y5 bound to both fibrils and globulomers, whereas ThT 
bound only to fibrils, as observed previously [8]. In addition, Shiga-Y17 
and Shiga-Y51 bound to the globulomers preferentially, showing much 
lower affinities for the Aβ fibrils. 
3.3. QCM analysis of intermediate Aβ aggregates over different 
aggregation periods 
We further investigated whether Shiga-Y51 bound to intermediate 
Aβ aggregates in the fibrillization process using QCM analysis with 
electrodes that were mounted with Aβ peptides incubated at 26 ◦C for 0, 
4, 8, and 12 h (Fig. 4; Supplementary Fig. 1B). QCM analysis showed 
that the most noticeable decrease in frequency was detected in Aβ 
peptides incubated for 4 h among these samples (Fig. 4a). Furthermore, 
Fig. 3. Total quantity of Shiga-Y compounds bound to Aβ fibrils and Aβ oligomers on the Au-coated QCM sensor. We estimated the quantities of Shiga-Y5 (a,e), 
Shiga-Y17 (b,f), Shiga-Y51 (c,g), and thioflavin T (d,h) that bound to Aβ fibrils (a–d) and oligomers (e–h) immobilized on the electrodes based on changes in fre-
quency over 20 min. We used solutions without Aβ fibrils and oligomers as controls (gray). The final concentration of each Shiga-Y compound was 10 μM, and the 
final thioflavin T concentration was 30 μM. We report values from the electrodes with immobilized Aβ fibrils and oligomers as the mean ± SEM of five measurements. 
We report the control values as the mean of three measurements performed with the electrode alone. Significance (Mann–Whitney test): *p < 0.05. 
Table 1 
Quantities of Shiga-Y compounds bound to Aβ oligomers and Aβ fibrils.  
Compound μM Oligomers (pmol) Fibrils (pmol) Oligomer/Fibril 
Shiga-Y5 10 71.1 55.1 1.29 
Shiga-Y17 10 69.8 27.7 2.52 
Shiga-Y51 10 59.5 23.1 2.57 
Thioflavin T 30 8.5 35.6 0.24 
We calculated the total quantity of Shiga-Y compounds that bound to the control 
and Aβ-immobilized electrodes after 20 min based on frequency changes. A 1 Hz 
frequency decrease corresponded to a 30 pg mass increase on the electrode. We 
quantified the Shiga-Y compounds bound to the oligomers and fibrils by sub-
tracting the total quantity of Shiga-Y compounds bound to the control electrodes 
from the total quantity bound to oligomers or fibrils that were immobilized on 
the electrodes. 
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there was a significant increase in the amount of Shiga-Y51 bound to the 
electrodes with Aβ peptides incubated for 4 h (p < 0.05; Fig. 4b), but not 
with Aβ peptides incubated for 0, 8, and 12 h. 
3.4. Shiga-Y51 inhibited the binding of curumin to Aβ globulomers 
Next, for further validation of the higher selectivity of Shiga-Y51 for 
Aβ oligomers over fibrils, we performed fluorescence competition assay. 
We observed no changes in the fluorescence of curcumin binding to Aβ 
fibrils in the presence of Shiga-Y51 at concentrations of 0.01–30 μM 
(Supplementary Fig. 3). In contrast, we observed a dose-dependent 
decline in the fluorescence of curcumin binding to Aβ oligomers in the 
presence of Shiga-Y51 (Supplementary Fig. 3). We were unable to obtain 
the IC50 value of Shiga-Y51 with regard to curcumin fluorescence for Aβ 
fibrils because of the absence of fluorescence inhibition; the IC50 value of 
Shiga-Y51 for Aβ oligomers was 34.61 μM. These results suggest that 
Shiga-Y51 competes with curcumin binding to Aβ globulomers, but not 
to Aβ fibrils. 
3.5. IMS analysis for the distribution of Shiga-Y51 
Our preliminary study detected Shiga-Y51 in the brain extract from 
the mouse intravenously injected with Shiga-Y51 (Supplementary Table 
1), which suggests the brain–blood barrier permeability of Shiga-Y51. 
To determine in vivo brain distribution of Shiga-Y51, we performed 
IMS on the mouse brain sections. First, we optimized the method to 
detect Shiga-Y51 ions using a matrix-assisted laser ionization detection 
(MALDI) system. We detected standard Shiga-Y51 ions at m/z 517.1, and 
the major fragment of the parent ions (m/z 517.1) at m/z 229.0 in the 
tandem mass spectrum (Fig. 5a and b). Next, we performed IMS analysis 
on brain sections from APP/PS1 mice injected with Shiga-Y51 (200 mg/ 
kg) or vehicle (n = 1 each) via the tail vein. Through IMS analysis, we 
detected high levels of Shiga-Y51 ions (m/z 517.1) and the fragment ions 
(m/z 229.0) in the mouse brain after Shiga-Y51 injection but not after 
vehicle injection (Fig. 5c–l). 
We further investigated the in vivo distribution of Shiga-Y51 in the 
brains of APP/PS1 mice using IMS. We detected intense signals (m/z 
517.1) in the cerebral cortex in the brain sections of APP/PS1 mice that 
were sacrificed 30 min after intravenous injection with Shiga-Y51 
(Fig. 5a–c). In contrast, in Shiga-Y51-injected wild-type mice we 
detected only faint signals in the cerebral cortex (Fig. 5d–f). 
3.6. Localization of Aβ oligomers in APP/PS1 mouse brains of APP/PS1 
mice 
Through immunohistochemical analysis we observed a large number 
of Aβ deposits mainly in the cerebral cortex, the hippocampus, and the 
thalamus in the brain of APP/PS1 mice (Fig. 6a). We also detected 
immunoreactivity for Aβ oligomers using 11A1 antibody in the same 
regions—namely, the cerebral cortex, hippocampus, and thalamus—in 
APP/PS1 mice (Fig. 6b). 
To investigate the correlation between the distributions of Shiga-Y51 
and oligomers, we measured signal intensities of the parent ion at m/z 
517.1 in IMS analysis and 11A1-immunoreactive areas in the cerebral 
cortex, hippocampus, hypothalamus, striatum, and corpus callosum. 
With Pearson’s correlation analysis we revealed significant correlation 
between the signal intensity of Shiga-Y51 in IMS analysis and 11A1- 
immunoreactivity (p < 0.05; Fig. 6e). 
3.7. Effects of Shiga-Y51 on the formation of oligomers and fibrils 
Finally, we investigated whether Shiga-Y51 affected the formation of 
Aβ oligomers and fibrils. Western blotting showed no obvious changes in 
bands of Aβ globulomers that formed in the presence or absence of 50 
μM Shiga-Y51 (Supplementary Fig. 4). For Aβ fibril formation, time- 
course analysis of changes in fluorescence intensity of ThT showed a 
time-dependent increase in ThT fluorescence when Aβ peptides were 
incubated in the absence of Shiga-Y51 (Supplementary Fig. 5). In 
contrast, the increase in ThT fluorescence was inhibited when Aβ pep-
tides were incubated in the presence of 10 μM Shiga-Y51 (Supplemen-
tary Fig. 5). These results suggest that Shiga-Y51 may inhibit the 
formation of Aβ fibrils by interacting with Aβ peptides at the early phase 
of Aβ aggregation when Aβ fibrils have not yet been formed, but has no 
effect on the formation of Aβ oligomers. 
4. Discussion 
In the present study, we showed that a novel curcumin derivative 
with a fixed keto form—Shiga-Y51—bound to Aβ oligomers in QCM 
analysis. Comparing the ratios of quantities of compounds binding to Aβ 
oligomers with those binding to Aβ fibrils, Shiga-Y51 had a relatively 
high selectivity to Aβ oligomers. Furthermore, IMS analysis demon-
strated that Shiga-Y51 passed the BBB, and bound to Aβ aggregates in 
the brains of APP/PS1 mice after an intravenous injection. These results 
suggest the potential of Shiga-Y51 as a seed compound targeting Aβ 
oligomers in the brain. 
Our previous study showed that curcumin and the derivatives with 
keto–enol tautomerism bound to Aβ fibrils in the enol form, and that the 
binding activity of the keto form to Aβ fibrils was much weaker [9]. In 
contrast, the present study revealed that Shiga-Y17 and Shiga-Y51—-
which are curcumin derivatives with fixed keto form—bound strongly to 
Aβ oligomers, and very weakly to Aβ fibrils in QCM analysis. Further-
more, QCM analysis showed a significant increase in the amount of 
Shiga-Y51 bound to Aβ peptides that were incubated in PBS for 4 h, but 
Fig. 4. Shiga-Y51 binds to early-to-intermediate aggregates in the Aβ fibrillization process. (a) Representative frequency changes over 20 min in QCM analysis of 
Shiga-Y51 with or without (Ctrl) Aβ peptides incubated at 26 ◦C for 0, 4, 8, and 12 h. (b) The amounts of Shiga-Y51 bound to the electrodes for 20 min in QCM 
analysis were calculated. Ctrl: control. Data are presented as means ± SEM. Significance was determined by one-way ANOVA followed by a Dunnett test. *p < 0.05. 
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Fig. 5. Imaging mass spectra (IMS) of brain sections from 
mice injected with Shiga-Y51. (a,b) We detected the Shiga-Y51 
ion at m/z 517.1 using a matrix-assisted laser ionization 
detection (MALDI) system. (a) MS spectrum of a Shiga-Y51 
standard and (b) the tandem mass spectrum. The major frag-
ment of the parent ion (m/z 517.1) detected at m/z 229.0 is 
indicated by the red arrow in (b). IMS imaging analysis and 
MALDI-MS spectra of brain sections from APP/PS1 mice that 
received an intravenous bolus injection of (c–g) Shiga-Y51 
(200 mg/kg) or (h–l) a vehicle. We show optical images in 
(c) and (h). IMS images of (d) the Shiga-Y51 parent ion (m/z 
517.1) and (e) the fragment ion (m/z 229.0) show intense 
signals in the cerebral cortex and hippocampus of an APP/PS1 
mouse injected with Shiga-Y51. Only weak signals are visible 
in the IMS images of a mouse injected with the vehicle (h–l). 
IMS images of brain sections from (m–o) APP/PS1 and (p–r) 
wild-type mice after receiving a continuous intravenous in-
jection of Shiga-Y51 (200 mg/kg, 0.5 mL/kg/min). IMS im-
ages of (n,q) the parent ion at m/z 517.1 and (o,r) the 
fragment ion at m/z 229.0. Signals from the cerebral cortex 
and hippocampus in the IMS image (m/z 517.1) of an APP/PS1 
mouse brain section (n) are more intense than those from a 
wild-type mouse brain (q). Optical images are shown in (m) 
and (p). ctx, cerebral cortex; hp, hippocampus; th, thalamus; 
st, striatum; cc, corpus callosum. Scale bar: 600 μm.   
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not for 8 and 12 h, suggests that Shiga-Y51 has binding activity against 
early-intermediate Aβ aggregates in the fibrillization process, and not to 
later aggregates. These findings suggest that the keto form, rather than 
the enol form, may be the binding form of curcumin derivatives to Aβ 
oligomers, which implies the promise of curcumin derivatives with fixed 
keto form as agents targeting Aβ oligomers. 
Entropy-driven processes are well known to play important roles in 
the formation of the three-dimensional structure of water soluble pro-
teins. That is, in a medium surrounded by water molecules, the hydro-
phobic amino acid residues tend to move inside of the protein molecule 
in order to avoid contact with water. This process is possible for proteins 
because they comprise long chains of amino acids. However, peptides 
such as Aβ cannot follow this process, because their amino acid chains 
are not long enough for extensive folding. Aggregation of Aβ seems to be 
necessary for such peptides containing hydrophobic amino acid residues 
in avoiding contact of these residues with water. Consequently these 
peptides form oligomers (such as dimers, trimers, tetramers, and so on). 
The Aβ oligomer is such a structure, as was recently confirmed by 
scanning tunneling microscopy [18]. Moreover, Irie proposed the 
possible structures of small oligomers, and indicated the hydrophobic 
nature of the cores in these oligomers [19]. The polypeptides in Aβ 
oligomers appear to bind to each other using their hydrophobic amino 
acid residues to form hydrophobic cores, and to incorporate hydro-
phobic molecules into their cores. 
Many PET imaging probes—including PiB, flutemetamol, florbeta-
ben, and florbetapir—have been developed for senile plaques which are 
formed by the aggregation of Aβ fibrils [20]. These probes seem to have 
a common feature—that is, a ring system which is co-planar and pos-
sesses π-electrons which are delocalized in the rings, and move freely 
within the them. These molecules are therefore flat and rather rigid, and 
seem to bind to Aβ fibrils easily, but have some difficulty entering the 
hydrophobic core of Aβ oligomers, because of their rigidity. 
However, suitable sized hydrophobic molecules with flexible struc-
tures could be incorporated within the hydrophobic core of Aβ oligo-
mers. If this hypothesis is correct, it is reasonable to state that the rather 
flexible molecules Shiga-Y17 and Shiga-Y51 (see Fig. 1) will bind readily 
to Aβ oligomers. The binding of Shiga-Y5 to both Aβ fibrils and Aβ 
oligomers is easily understood, because it is an equilibrium (tautomeric) 
mixture of keto- and enol-forms (see Fig. 1)—its rather rigid enol form 
binding to Aβ fibrils and the more flexible keto form binding to Aβ 
oligomers. Our experimental results are consistent with these 
statements. 
Although in clinical trials many attempts to target Aβ have failed, the 
human monoclonal antibody Aducanumab recently displayed signifi-
cant efficacy in Alzheimer phase 3 trials [21,22]. Since Aducanumab 
targets both Aβ fibrils and soluble Aβ oligomers, it has been suggested 
that Aβ oligomers play a central role in AD pathogenesis [21,22]. 
Accordingly, evaluation of Aβ oligomer levels in the in vivo brain would 
be of great importance in monitoring disease progression in AD. Previ-
ous studies, such as BoDipy-Oligomer (BD-Oligo) [23], F-SLOH [24], 
CRANAD-102 [25], PTO-29 [26], and DCM-AN [27], have reported 
several near infrared fluorescent imaging probes that selectively labeled 
Aβ oligomers in the in vivo brain. In the present study, Shiga-Y51 
accumulated in APP/PS1 mice after systemic injection, suggesting cur-
cumin derivatives with a fixed keto form as a potential seed structure for 
imaging probes targeting Aβ oligomers. Further study aimed at the 
synthesis of derivatives with greater selectivity to Aβ oligomers—and 
their development as an imaging probe for PET or other modal-
ities—would be of great interest. 
In the present study, we found no inhibitory effects on the formations 
of Aβ oligomers. In contrast, regarding Aβ fibril formation, the increase 
in ThT fluorescence was inhibited when Aβ peptides were incubated 
with Shiga-Y51. This result suggests that Shiga-Y51 may inhibit the 
formation of Aβ fibrils by interacting with Aβ peptides at the early phase 
of Aβ aggregation when Aβ fibrils have not yet been formed. However, 
there is also a possibility that, at β-sheeted structures, Shiga-Y51 com-
petes with ThT binding to Aβ fibrils, which may also lead to a decrease in 
ThT fluorescence. It would therefore be difficult to draw conclusions as 
to the effects of Shiga-Y51 on the formations of Aβ oligomers and fibrils, 
based only on limited experiments. Further study aiming to reveal the 
therapeutic effect of Shiga-Y51 in inhibiting the formation of Aβ oligo-
mers and fibrils remains the aim of future work. 
Our study suffered from some limitations. First, we used globulomers 
[12], which were prepared from synthetic Aβ 1–42 peptides to serve as a 
model of Aβ oligomers. However, various species of Aβ oligomers differ 
in size, secondary structure, and cytotoxicity [28,29]. Therefore, it is 
still unclear whether Shiga-Y51 binds to globulomers specifically or Aβ 
oligomers in general. Second, we used APP/PS1 mice, in which Aβ 
oligomers and fibrils accumulate in the same region of the brain. It is 
therefore quite challenging to demonstrate whether Shiga-Y5 binds 
specifically to Aβ oligomers in the brains of APP/PS1 mice. We next plan 
to use APP E693Δ (Osaka mutation) transgenic mice—which show 
Fig. 6. Immunohistochemical analysis for Aβ oligomers in the brain of APP/PS1 mice. Representative photographs showing immunohistochemistry for Aβ (a,c) and 
Aβ oligomers that was detected with anti-Aβ E22P antibody (clone 11A1; b,d) in APP/PS1 (a,b) and wild-type mice (c,d). Scale bar: 1 mm. (e) Pearson’s correlation 
analysis revealed significant correlation of 11A1-immunoreactive areas and signal intensities of IMS analysis in the cerebral cortex (ctx), hippocampus (hp), thalamus 
(th), striatum (st), and corpus callosum (cc) in APP/PS1 mice (n = 2) (p < 0.05). 
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predominant accumulation of Aβ oligomers in the brain—to demon-
strate the in vivo binding of Shiga-Y51 to Aβ oligomers. Lastly, to sup-
port the theory that the enol form of curcumin derivatives binds to Aβ 
fibrils and the keto form binds to Aβ oligomers, it might be interesting to 
investigate whether the enol form is able to bind to Aβ oligomers. We 
were unable to investigate this question, because, due to the chemical 
properties of the curcumin derivative with fixed enol form, it was not 
easy to perform QCM analysis. 
5. Conclusions 
Here we demonstrated the binding activity of Shiga-Y51 to Aβ olig-
omers. In addition, Shiga-Y51 showed BBB permeability and in vivo 
binding to Aβ aggregates in the brain of an AD mouse model. Detecting 
Aβ oligomers in the in vivo brain would be critically important in un-
derstanding the etiology of AD. Furthermore, considering the recent 
failures of clinical trials targeting Aβ monomers, targeting Aβ oligomers 
has become attractive as a therapeutic approach in AD. Therefore, 
although further efforts are needed, Shiga-Y51 is a first-generation 
compound targeting Aβ oligomers. 
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